Drug Trial Radar · NCT06488209
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Jul 29, 2022
Primary completion
Apr 3, 2025
Study completion Apr 3, 2025
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
Conditions
- Healthy Volunteers
- Autoimmune Disease
Interventions
LAD191Drug
LAD191 SC injection.
PlaceboOther
Matching placebo SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEsTime frame: Baseline up to Day 73
- Part 1: Number of Participants who have Dose-limiting Adverse ReactionsTime frame: Baseline up to Day 73
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 73
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Physical Examination FindingsTime frame: Baseline up to Day 73
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Electrocardiograms (ECGs) ParametersTime frame: Baseline up to Day 73
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 73
- Part 2 and 3: Number of Participants with Adverse Events (AEs) and Severity of AEsTime frame: Baseline up to Day 94
- Part 2 and 3: Number of Participants who have Dose-limiting Adverse ReactionsTime frame: Baseline up to Day 94
- Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 94
- Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Physical Examination FindingsTime frame: Baseline up to Day 94
- Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in ECGs ParametersTime frame: Baseline up to Day 94
- Part 2 and 3: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 94
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Doral Medical Research
Miami, Florida
Jennifer Parish, MD
Philadelphia, Pennsylvania
ICON Early Phase Services, LLC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.